The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 324.00
Bid: 285.00
Ask: 345.00
Change: 0.00 (0.00%)
Spread: 60.00 (21.053%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 324.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: Oxford BioMedica bullish; Petrofac slumps

Mon, 29th Apr 2024 10:42

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

----------

SMALL-CAP - WINNERS

----------

Oxford BioMedica PLC, up 6.9% at 244.25 pence, 12-month range 164.29p-474.50p. The gene and cell-therapy company says it is seeing decent demand for its contract development and manufacturing organisation offering, as it moves away from the Covid-19 vaccine era. Oxford BioMedica's revenue in 2023 falls 36% to GBP89.5 million from GBP140.0 million and its pretax loss stretches to GBP188.5 million from GBP46.0 million. Hurting its bottom line is a GBP99.3 million impairment of assets booked in the US business, "driven by the cessation of revenues from Homology". Homology Medicines Inc is a genetic medicines company and client of Oxford Biomedica US. More promisingly, Oxford BioMedica reports a "small increase in core business" revenue. Chief Executive Officer Frank Mathias comments: "2023 was a year of transformation for Oxford Biomedica. We are building our position as a global pure-play cell and gene therapy CDMO and through our 'One OXB' strategy are unifying our operations in the UK, US and the EU, including our newly-acquired sites in France...Despite challenging market conditions, we continue to see strong demand for our CDMO services, further solidifying our position as a world-leading global CDMO in the rapidly expanding cell and gene therapy market."

----------

Digital 9 Infrastructure PLC, up 3.9% at 22.03 pence, 12-month range 14.50p-72.00p. The investor in internet infrastructure, such as data centres and subsea fibre receives a USD25 million deferred consideration payment in connection with its sale of Verne Global. Digital 9 plans an additional GBP47 million repayment and partial cancellation of its revolving credit facility.

----------

SMALL-CAP - LOSERS

----------

Petrofac Ltd, down 31% at 15.46p, 12-month range 13.91p-87.50p. It warns a financial restructuring could see a chunk of its debt converted to equity, resulting in dilution of existing shareholders. The energy infrastructure company also flags an extra USD130 million charge in its engineering and construction division and said the release of full-year results would be delayed.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
28 Jan 2022 16:19

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

Read more
28 Jan 2022 12:13

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

Read more
28 Jan 2022 10:27

Oxford BioMedica to acquire 80% ownership of new US virus business

Oxford BioMedica to acquire 80% ownership of new US virus business

Read more
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.